Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013893 | 0.84 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3R1PIK3CBMERTK | |
| SCHEMBL2013924 | 0.83 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3R1PIK3CBMERTK | |
| SCHEMBL16039607 | 0.83 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3R1PIK3CBMERTK | |
| SCHEMBL2013767 | 0.82 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3R1PIK3CBMERTK | |
| SCHEMBL2014609 | 0.82 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3R1PIK3CBMERTK | |
| SCHEMBL2043447 | 0.82 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3R1PIK3CBMERTK | |
| SCHEMBL2054056 | 0.82 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3R1PIK3CBMERTK | |
| SCHEMBL2017292 | 0.81 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3R1PIK3CBMAP4K4 | |
| SCHEMBL16039642 | 0.81 | PIK3CD (0.42) | PIK3CDPIK3CGPIK3R1PIK3CBMERTK | |
| SCHEMBL2017510 | 0.80 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3R1PIK3CBMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | claimed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | claimed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | claimed |
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-08-04 | — | — | US | claimed |
| WO-2011075643-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | claimed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-08-04 | — | — | US | disclosed |
| WO-2011075643-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3CG 10/4885PIK3R1 11/4885 |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3CG 10/4885PIK3R1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.